A Phase 3b, Non-randomized, Open Label, Multi-country, Cohort Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) During Any Pregnancy Conceived Post Vaccination/Control
Latest Information Update: 01 Mar 2025
At a glance
- Drugs GSK-3888550A (Primary) ; DTaP vaccine; GSK 2321138A
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RSV MAT-015
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
Most Recent Events
- 24 Feb 2025 Status changed from recruiting to completed.
- 19 Sep 2024 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 17 Sep 2024 This trial has been completed in Belgium, according to European Clinical Trials Database record.